| Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3 X Hu, Y Meng, L Xu, L Qiu, M Wei, D Su, X Qi, Z Wang, S Yang, C Liu, ... Cell death & disease 10 (2), 104, 2019 | 38 | 2019 |
| Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy Y Meng, L Qiu, X Zeng, X Hu, Y Zhang, X Wan, X Mao, J Wu, Y Xu, ... Signal Transduction and Targeted Therapy 7 (1), 388, 2022 | 36 | 2022 |
| Mechanism of cancer: Oncohistones in action L Qiu, X Hu, Q Jing, X Zeng, KM Chan, J Han Journal of Genetics and Genomics 45 (5), 227-236, 2018 | 32 | 2018 |
| miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1 Y Meng, X Hu, S Li, X Zeng, L Qiu, M Wei, Z Wang, J Han BMC cancer 20, 1-14, 2020 | 30 | 2020 |
| IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB–and caspase-8–dependent mechanisms L Zhou, Y Zhang, MB Meads, Y Dai, Y Ning, X Hu, L Li, K Sharma, ... Blood Advances 5 (19), 3776-3788, 2021 | 11 | 2021 |
| Dual mTORC1/2 inhibition synergistically enhances AML cell death in combination with the BCL2 antagonist venetoclax T Satta, L Li, SL Chalasani, X Hu, J Nkwocha, K Sharma, M Kmieciak, ... Clinical Cancer Research 29 (7), 1332-1343, 2023 | 6 | 2023 |
| Synergistic interactions between the hypomethylating agent thio-deoxycytidine and venetoclax in myelodysplastic syndrome cells X Hu, L Li, J Nkwocha, K Sharma, L Zhou, S Grant Hematology Reports 15 (1), 91-100, 2023 | 5 | 2023 |
| Chk1 inhibition potently blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding activity, and activation of downstream targets in human multiple myeloma Cells L Zhou, X Pei, Y Zhang, Y Ning, L Li, X Hu, SL Chalasani, K Sharma, ... Molecular Cancer Research 20 (3), 456-467, 2022 | 5 | 2022 |
| Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or‐resistant myeloma cells Y Leng, X Hu, L Li, J Nkwocha, T Satta, K Sharma, M Kmeiciak, H Zhou, ... Hematological Oncology 40 (5), 999-1008, 2022 | 3 | 2022 |
| Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells L Li, X Hu, J Nkwocha, K Sharma, M Kmieciak, H Mann, L Zhou, S Grant Cellular Oncology 46 (5), 1369-1380, 2023 | 2 | 2023 |
| Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo L Li, X Hu, J Nkwocha, M Kmieciak, MB Meads, KH Shain, RR Alugubelli, ... British Journal of Haematology, 2024 | | 2024 |
| Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells L Li, X Hu, J Nkwocha, K Sharma, L Zhou, S Grant Leukemia Research 121, 106944, 2022 | | 2022 |
